• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: C.R. BARD, INC. (GFO) LUTONIX 035 DRUG COATED BALLOON PTA CATHETER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

C.R. BARD, INC. (GFO) LUTONIX 035 DRUG COATED BALLOON PTA CATHETER Back to Search Results
Model Number 9004
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Code Reocclusion (1985)
Date of Event 11/29/2016
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
Analysis: the samples were discarded by the user facility; therefore, device evaluations are unable to be performed.A lot history review revealed 3 additional reocclusion complaints were associated with this lot.A review of the device history record (dhr) indicates the lot was manufactured to specification.Conclusion: the actual samples were not received for evaluation.The dhr found nothing to indicate a manufacturing related cause for this event.The investigator assessed the event was not related to the study devices or procedure.Based on the instructions for use (ifu), the occurrence of reocclusion is an inherent risk of any pta procedure, and has been reported in clinical trials of drug coated balloons.If additional information becomes known to the manufacturer, a supplemental report will be provided with all relevant information.
 
Event or Problem Description
It was reported through a clinical registry that during the index procedure, two lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheters were used to treat the target lesion located in the left mid-distal superficial femoral artery (sfa).Approximately 12 months after the index procedure, the patient¿s left sfa vasculature was reportedly reoccluded via duplex ultrasound (dus) imaging.A revascularization was performed and the health care professional (hcp) deemed it was successful.The investigator assessed that the event was not related to the study devices or procedure.The samples were discarded by the user facility and are not available for evaluation.No adverse patient effects were reported.This is one of two products involved with the reported event and the associated manufacturer¿s report number is 3006513822-2018-00282.
 
Event or Problem Description
It was reported through a clinical registry that during the index procedure, two lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheters were used to treat the target lesion located in the left mid-distal superficial femoral artery (sfa).Approximately 12 months after the index procedure, the patient¿s left sfa vasculature was reportedly reoccluded via duplex ultrasound (dus) imaging.A revascularization was performed and the health care professional (hcp) deemed it was successful.The investigator assessed that the event was not related to the study devices or procedure.The samples were discarded by the user facility and are not available for evaluation.No adverse patient effects were reported.This is one of two products involved with the reported event and the associated manufacturer¿s report number is 3006513822-2018-00281.
 
Additional Manufacturer Narrative
Corrected data: b.5 the event description had the following number "282" changed to "281." h3 analysis: the samples were discarded by the user facility; therefore, device evaluations are unable to be performed.A lot history review revealed 3 additional reocclusion complaints were associated with this lot.A review of the device history record (dhr) indicates the lot was manufactured to specification.Conclusion: the actual samples were not received for evaluation.The dhr found nothing to indicate a manufacturing related cause for this event.The investigator assessed the event was not related to the study devices or procedure.Based on the instructions for use (ifu), the occurrence of reocclusion is an inherent risk of any pta procedure, and has been reported in clinical trials of drug coated balloons.If additional information becomes known to the manufacturer, a supplemental report will be provided with all relevant information.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
LUTONIX 035 DRUG COATED BALLOON PTA CATHETER
Common Device Name
DRUG COATED BALLOON PTA CATHETER
Manufacturer (Section D)
C.R. BARD, INC. (GFO)
289 bay road
queensbury NY 12804
MDR Report Key8144100
Report Number3006513822-2018-00282
Device Sequence Number16616212
Product Code ONU
UDI-Device Identifier00801741088568
UDI-Public(01)00801741088568
Combination Product (Y/N)N
Initial Reporter StateIL
Initial Reporter CountryUS
PMA/510(K) Number
P130024
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source health professional,other,stu
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 12/12/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date07/16/2017
Device Model Number9004
Device Catalogue NumberLX35130640
Device Lot NumberGFZG1973
Was Device Available for Evaluation? No
Event Location Hospital
Initial Date Received by Manufacturer 11/15/2018
Supplement Date Received by Manufacturer12/11/2018
Initial Report FDA Received Date12/07/2018
Supplement Report FDA Received Date12/12/2018
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
BOSTON SCIENTIFIC CHARGER 5X100; BOSTON SCIENTIFIC CHARGER 5X100; BOSTON SCIENTIFIC CHARGER 5X25; BOSTON SCIENTIFIC CHARGER 5X25; LX351306120 LOT# LUZE0022; LX351306120 LOT# LUZE0022; TACK ENDOVASCULAR SYSTEM; TACK ENDOVASCULAR SYSTEM
Outcome Attributed to Adverse Event Required Intervention;
Patient Age42 YR
Patient Weight119
-
-